Aims

  • We used the PHD to:
    • Estimate the rate of in-hospital mortality, the length of hospital stay and the rate of hospital readmission among US patients with IPF in the era following FDA approval of antifibrotic drugs.
    • Determine patient-, hospital- and treatment-related factors associated with in-hospital mortality, hospital stay and readmission.
Header - Navigation Icon
Header - Navigation Icon
 Introduction
Header - Navigation Icon
 Methods

This study was funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) as a collaboration with the Duke Clinical Research Institute and Premier, Inc.